US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Precision BioSciences, Inc. - Common Stock
(NQ:
DTIL
)
6.310
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Precision BioSciences, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review
↗
October 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novavax Shares React to Reports Of Manufacturing Issues With Its COVID-19...
Via
Benzinga
Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)
September 27, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Appoints Michael Amoroso Chief Executive Officer
September 27, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
↗
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 10, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences, iECURE Ink Licensing Pact For Gene Editing Therapies
↗
September 09, 2021
Precision BioSciences Inc (NASDAQ: DTIL) and iECURE announced a license and collaboration agreement. Under the agreement iECURE plans to advance Precision's PBGENE-...
Via
Benzinga
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
↗
September 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:...
Via
Benzinga
Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline
September 09, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies
September 09, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications
↗
September 02, 2021
Precision BioSciences Inc (NASDAQ: DTIL) and Tiziana Life Sciences plc (NASDAQ: TLSA) have announced an exclusive license agreement for Tiziana's...
Via
Benzinga
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
September 02, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
↗
September 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV...
Via
Benzinga
Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021
August 25, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
↗
August 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...
Via
Benzinga
Precision BioSciences: Q2 Earnings Insights
↗
August 12, 2021
Shares of Precision BioSciences (NASDAQ:DTIL) rose 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 157.14% year...
Via
Benzinga
Precision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business Update
August 12, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Report Second Quarter 2021 Financial Results on August 12, 2021
August 05, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Starts Dosing In Blood Cancer Trial With CAR T Therapy
↗
July 01, 2021
Precision BioSciences Inc (NASDAQ: DTIL) has dosed the first patient in its Phase 1 trial with PBCAR19B in patients with relapsed/refractory (R/R) non-Hodgkin...
Via
Benzinga
Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma
July 01, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
60 Biggest Movers From Yesterday
↗
June 29, 2021
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its...
Via
Benzinga
44 Stocks Moving In Monday's Mid-Day Session
↗
June 28, 2021
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software...
Via
Benzinga
Precision BioSciences Moves Higher After Commencing Dosing In PBCAR269A Combination Arm Of Multiple Myeloma Trial
↗
June 28, 2021
Precision BioSciences Inc (NASDAQ: DTIL) and SpringWorks Therapeutics Inc (NASDAQ: SWTX) have dosed the first patient in the combination arm of Precision...
Via
Benzinga
Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma
June 28, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
24 Stocks Moving in Monday's Pre-Market Session
↗
June 28, 2021
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim...
Via
Benzinga
Precision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma
June 04, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo
June 01, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
↗
May 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)...
Via
Benzinga
Precision BioSciences Appoints Alex Kelly as Chief Financial Officer
May 27, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Participate in the Jefferies Virtual Healthcare Conference
May 26, 2021
From
Precision BioSciences Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
May 20, 2021
Gainers Enveric Biosciences (NASDAQ:ENVB)...
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
